dermatitis/edema

TECHNICAL FIELD The present invention relates to a composition for preventing or treating atopic dermatitis, the composition including, as an active ingredient, X-shaped DNA formed by complementary binding of four oligonucleotides. BACKGROUND ART Atopy is a word of the Greek origin which means

This application is a National Stage Application under 35 U.S.C. .sctn.371 of PCT/KR2010/007523, filed 29 Oct. 2010, which claims the benefit of priority to Korean Patent Application No. 10-2010-0093901, filed 28 Sep. 2010, the disclosures of all of which are hereby incorporated by reference in

The present invention relates to indolylmaleimide derivatives, process for their production and pharmaceutical compositions containing them. More particularly the present invention provides a compound of formula I ##STR00002## wherein R.sub.a is H; CH.sub.3; CH.sub.2--CH.sub.3; or isopropyl, R.sub.b

The present invention relates to indolylmaleimide derivatives, process for their production and pharmaceutical compositions containing them. More particularly the present invention provides a compound of formula I ##STR00002## wherein R.sub.a is H; CH.sub.3; CH.sub.2--CH.sub.3; or isopropyl, R.sub.b

The present invention relates to indolylmaleimide derivatives, process for their production and pharmaceutical compositions containing them. More particularly the present invention provides a compound of formula I ##STR00002## wherein R.sub.a is H; CH.sub.3; CH.sub.2--CH.sub.3; or isopropyl, R.sub.b

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention is broadly directed to a method of inhibiting or decreasing vascular permeability associated with dermal edema, e.g., induration, and especially the increased vascular permeability induced by vascular permeability factor

This Application is a 371 of PCT/JP2005/000323, filed Jan. 6, 2005; the disclosure of which is incorporated herein by reference. DETAILED DESCRIPTION OF THE INVENTION 1. Technical Field The present invention relates to a therapeutic agent for diseases in which corticotropin releasing factor (CRF) is

This Application is a 371 of PCT/JP2005/000319, filed Jan. 6, 2005. DETAILED DESCRIPTION OF THE INVENTION 1. Technical Field The present invention relates to a therapeutic agent for diseases in which corticotropin releasing factor (CRF) is considered to be involved, such as depression, anxiety,

This Application is a 371 of PCT/JP2005/000318, filed Jan. 6, 2005; the disclosure of which is incorporated herein by reference. DETAILED DESCRIPTION OF THE INVENTION 1. Technical Field The present invention relates to a therapeutic agent for diseases in which corticotropin releasing factor (CRF) is

DETAILED DESCRIPTION OF THE INVENTION 1. Technical Field The present invention relates to a therapeutic agent for diseases in which corticotropin releasing factor (CRF) is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating

DETAILED DESCRIPTION OF THE INVENTION 1. Technical Field The present invention relates to a therapeutic agent for diseases in which corticotropin releasing factor (CRF) is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating

FIELD OF THE INVENTION The invention relates to the use of biologically active glutarimide derivatives or pharmaceutically acceptable salts thereof as agents for the treatment of eosinophilic diseases. BACKGROUND Eosinophils are cells of the innate immunity. They are produced in the bone marrow and

BACKGROUND OF THE INVENTION The present invention concerns pharmaceutical compositions which include urea and hyaluronic acid or derivatives of hyaluronic acid. The present invention further concerns methods of treating disease of the cutis, anorectal epithelium and rectal mucosa employing the

BACKGROUND OF THE INVENTION The present invention concerns pharmaceutical compositions which include urea and hyaluronic acid or derivatives of hyaluronic acid. The present invention further concerns methods of treating disease of the cutis, anorectal epithelium and rectal mucosa employing the

BACKGROUND OF THE INVENTION The present invention concerns pharmaceutical compositions which include urea and hyaluronic acid or derivatives of hyaluronic acid. The present invention further concerns methods of treating disease of the cutis, anorectal epithelium and rectal mucosa employing the